FOXP3 and obesity disorder: In-vivo administration of β3 adrenergic receptor agonist CL-316243, which was once used for treatment of obesity and type 2 diabetes (92), enhanced abundance of Foxp3+ CD4+ T cells in inguinal lymph nodes as well as in adipose tissues, including BAT, SAT, and VAT (13).